Description: YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
Home Page: cj.hec.cn
No. 38, Binjiang Road
Yichang,
China
Phone:
86 769 8176 8886
Officers
| Name | Title |
|---|---|
| Mr. Juncai Jiang | GM & Exec. Director |
| Mr. Qiang Zhang | CFO & Head of Fin. Department |
| Mr. Yangui Chen | Head of the Sales Department & Exec. Director |
| Mr. Danjin Wang | Deputy GM & Exec. Director |
| Mr. Shuang Li | Deputy GM & Exec. Director |
| Mr. Qiyun Peng | Joint Company Sec. |
| Mr. Shengchao Wang | Chief of Quality Division & Employee Representative Supervisor |
| Mr. Wai Chiu Wong FCS | Joint Company Sec. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0955 |
| Price-to-Sales TTM: | 3.3402 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3919 |